- Home
- ALLE vs BMRN Comparison
ALLE vs BMRN Comparison
Compare ALLE & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLE
- BMRN
- Stock Information
- Founded
- ALLE 2013
- BMRN 1996
- Country
- ALLE Ireland
- BMRN United States
- Employees
- ALLE N/A
- BMRN N/A
- Industry
- ALLE Diversified Commercial Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ALLE Consumer Discretionary
- BMRN Health Care
- Exchange
- ALLE Nasdaq
- BMRN Nasdaq
- Market Cap
- ALLE 12.7B
- BMRN 11.3B
- IPO Year
- ALLE N/A
- BMRN 1999
- Fundamental
- Price
- ALLE $167.20
- BMRN $57.54
- Analyst Decision
- ALLE Hold
- BMRN Buy
- Analyst Count
- ALLE 9
- BMRN 23
- Target Price
- ALLE $163.67
- BMRN $93.14
- AVG Volume (30 Days)
- ALLE 1.1M
- BMRN 2.5M
- Earning Date
- ALLE 07-24-2025
- BMRN 08-04-2025
- Dividend Yield
- ALLE 1.22%
- BMRN N/A
- EPS Growth
- ALLE 14.50
- BMRN 154.69
- EPS
- ALLE 7.20
- BMRN 3.40
- Revenue
- ALLE $3,876,600,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- ALLE $7.84
- BMRN $12.34
- Revenue Next Year
- ALLE $6.00
- BMRN $10.01
- P/E Ratio
- ALLE $23.21
- BMRN $16.93
- Revenue Growth
- ALLE 5.49
- BMRN 18.36
- 52 Week Low
- ALLE $116.57
- BMRN $52.93
- 52 Week High
- ALLE $170.11
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- ALLE 66.04
- BMRN 47.03
- Support Level
- ALLE $163.06
- BMRN $56.45
- Resistance Level
- ALLE $170.11
- BMRN $58.62
- Average True Range (ATR)
- ALLE 2.51
- BMRN 1.95
- MACD
- ALLE -0.26
- BMRN -0.25
- Stochastic Oscillator
- ALLE 58.72
- BMRN 15.51
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.